Leukapheresis Market - Global Industry Analysis, Growth, Key Trends, Regional Assessment, and Forecast 2020 - 2030
Leukapheresis is a laboratory procedure to separate white blood cells from a sample of blood which can occur with chronic lymphocytic leukemia (CLL). Leukapheresis is a good treatment option for patients who have very high white blood cell count or to obtain white blood cells for later transplant to treat decrease in white blood cells during chemotherapy. It also helps fighting prostate cancer and other form of cancers.
Earlier, leukapheresis was designed for palliative treatment for leukemia with only limited efficacy. But later as this technique was used for treatment modality for hyperleukocytic acute myeloid leukemia, and now it is also used to collect granulocytes to transfuse into neutropenic patients with bacterial or fungal infections, the growth of adoption of this technique is expected to increase.
How Leukapheresis is important for CAR or Adaptive Cell Therapy Manufacturing?
Chimeric antigen receptor (CAR) T cell therapy may be offered to people when their cancer comes back. Leukapheresis is the first step in this treatment. Research is going on for this treatment. Researchers want to collect T cells from people who may become eligible for a CAR T-cell study in the future. Leukapheresis is an essential step for CAR therapy or other adaptive cellular therapy products. The procedure is required to develop a streamlined process where patients have to undergo apheresis for development of a CAR cell or other adoptive cell therapy product. Once patient meets the eligibility conditions for one of the NCI CAR clinical cell therapy trials, they will undergo leukapheresis estimated by recipient weight and target cell harvest dose in Department of Transfusion Medicine (DTM). Therefore, need for leukapheresis in CAR therapy is a major factor for the boost in its adoption.
Prevalence of Leukemia Is projected to Boost the Treatment
Cases of leukemia have been increasing significantly. According to American Cancer Society, in 2020, there were 60,530 new cases of all kinds of leukemia which witnessed 23,100 deaths. Acute myeloid leukemia being the most prevalent accounted for 19,940 cases in US. The cancer burden in Europe is estimated to have risen to 2.7 million new cases and 1.3 million deaths in Europe as per the Joint Research Centre in European Union. Therefore, it is expected that the rising cases of leukemia and cancer may pave a way of growth for leukapheresis.
Side Effects of Leukapheresis may restrain the Growth
Like any other medical treatment, leukapheresis also have some risks and side effects which may decline its growth. Hypocalcemia, anemia, local or systematic infections may occur among the patients. Hypocalcemia is an irregular drop of calcium from the body when white blood cells are extracted. The lack of calcium in the body may cause numbness, muscle spasms, etc. Anaemia can also occur due to low count of red blood cells or platelets which may happen during the process. Although, in most of the cases, the effect of anaemia is mild. Local or systematic infections, redness and bruising at the vein puncture may also happen. All these side effects can cause the patients to decline the treatment if it is not very important.
Alternative Technologies may Cause Hindrance in Market Boost
As per the research article by pnas.org, clinical leukapheresis can concentrate mononuclear cells from almost the entire blood volume, but such large numbers and cell concentrations are incompatible with such technology. Therefore, an ultra-high throughput microfluidic chip, CTC-iChip rapidly sorts through an entire leukapheresis product of over 6 billion nucleated cells, increasing the CTC isolation capacity by two orders of magnitude. CTC based liquid biopsies provide cancer diagnostics, treatment selection, and response monitoring. Therefore, these factors may cause restrain to the leukapheresis market during the forecast period.
Prominent players in the market include Caltag Medsystems Limited (UK), BioIVT (US), Asahi Kasei Medical Co. Ltd. (Japan), Terumo BCT, Inc. (US), MEDICA S.p.A (Italy), StemExpress, LLC (US), AllCells, LLC (US), Charles River Laboratories (US), Lonza Group AG (Switzerland), Macopharma SA (France), PuriBlood Medical Co. Ltd. (Taiwan), Miltenyi Biotec (Germany), ZenBio (US), Discovery Life Sciences (US), Intelligent Tissue Group (US), Haemonetics Corporation (US), etc.
AllCells, LLC, a leading provider of prmary cells supporting biomedical research announced in September 2020 about the addition of Cyropreserved Leukppaks to their extensive product portfolio. The primary cells are of high quality due to on-site facilities. These cells are cryopreserved using GE Healthcare’s GMP-compliant VIA freeze quad controlled rate freezer which is capable of consistently high post recovery and viability. Cryopreserved cells are flexible and thus, experiments on them can be done as per the schedule without waiting on delivery of fresh cells.
Novartis in October 2020 announced the authorization from Japan’s Ministry of Health, labour and Welfare for a site for manufacturing of commercial CAR-T cell therapy for patients in Japan. The commercial is the first to get approval in Asia. The company’s aim is to being treatment closer to patients. Kymriah is the first ever FDA approved CAR-T cell therapy, and the first ever CAR-T to be approved in two distinct indications. Kymriah is currently approved for the treatment of pediatric and young adults of acute lymhoblastic leukemia.
Haemonetics Corporation, Boston based company have made an agreement to sell its Fajardo, Puerto Rico manufacturing operations to filter GVS. The company will retain all intellectual property rights to its proprietary blood filters which are currently manufactured at their Fajardo facility. The company has offered exclusive rights to manufacture and supply the blood filters. Thus, Fajardo facility will become GVS employees.
The major contributors towards the growth of leukapheresis include, increasing incidences of leukemia, growing demand for leukapheresis procedures, research applications, growing demand for leukopaks for research applications, etc.
North America is expected to hold the dominating share owing to rise in geriatric population, increasing cases of leukemia. According to Leukemia and Lymphoma Society, approximately every 3 minutes, one person is diagnosed with leukemia in US and in 9 minutes someone dies. According to American Cancer Society, 60,530 new cases of all kinds of leukemia were diagnosed in 2020 which witnessed 23,100 deaths. Acute myeloid leukemia is the most prevalent and accounted for 19,940 cases in US. North Ameirca is one of the leading countries to record deaths due to cancer and leukemia. Furthermore, research and development and new technological advancements are another factor for the market growth.
European region is also expected to have a significant growth during the forecast period 2021-2031. The acute promyelocytic leukemia which is a rare disease also accounted for 2.5 per million person in Italy, 1.39 per million in Spain, 0.54 per million in Great Britain, 0.4 per million in France according to frontiers.org. Growing AML cases are also the concerning topic, it is expected that the cases will increase by 17% by 2027, therefore increasing the growth of its treatment options. All these factors offer a contribution towards the growth of increasing leukapheresis market.
In Asia, China and Pakistan account for 36.2% and 43.5% in AML cases. Increasing medical infrastructure, emerging technologies, increasing trials and investments due to rising geriatric population, and cases of leukemia is paving the way for market growth. As per Globocan, over 20,000 new cases of childhood blood cancer are detected in India of which almost 15,000 cases are of leukemia. China is expected to witness increase over 14,000 cases of acute lymphocytic leukemia by 2029, therefore, rising incidences are projected to grow the adoption of leukapheresis.
Based on Type
Based on Application
Based on End user
Based on Region
Key Questions Answered
BioIVT (US), Asahi Kasei Medical Co. Ltd. (Japan), Terumo BCT, Inc. (US), MEDICA S.p.A (Italy), StemExpress, LLC (US), AllCells, LLC (US), Charles River Laboratories (US), etc.
Blood component providers and blood centres due to increasing number of blood donations.
Centrifugal devices segment owing to favourable reimbursement policies for therapeutic apheresis devices and its use for blood component donations.
Pharmaceuticals, hospitals, transfusion centres, etc.
North America, especially US.
The reports at TMR Research provide qualitative solutions that break the barriers of doubt or uncertainties when the stakeholders plan to expand their growth reach. The researchers compile the necessary information that enlightens the CXOs about the current growth opportunities in a specific market and enables them to make the most of the opportunities.
TMR Research is a leader in developing well-researched reports. The expertise of the researchers at TMR Research makes the report stand out from others. TMR Research reports help the stakeholders and CXOs make impactful decisions through a unique blend of innovation and analytical thinking. The use of innovation and analytical thinking while structuring a report assures complete and ideal information of the current status of the market to the stakeholders.
TMR Research has rich experience in developing state-of-the-art reports for a wide array of markets and sectors. The brilliance of the experts at TMR Research and their alacrity to conduct thorough research and create phenomenal reports makes TMR Research better than others.
5-Point Growth Formula
The 5-point growth formula developed by TMR Research provides an insight to the stakeholders and CXOs about the current situation in the market. The growth formula makes the report a perfect companion for the stakeholders and CXOs.
The 5-point growth formula includes the following points:
Current and Future Threats
Along with studying the opportunities necessary for growth, threats are also an important aspect to look upon for the companies and stakeholders in a specific sector. TMR Research studies every negative aspect that will hinder the growth of a specific area of business and includes it in the report. The stakeholders and CXOs will have the benefit of assessing the threat and take the necessary steps to prevent the hindrance caused due to the threats.
Accurate Trend Analysis
Keeping up with the latest trends is crucial in any business or sector. While stakeholders are aware of the trends that are on the surface, TMR Researchers find trends that are deeply entrenched in the particular market or sector. The reports are constantly updated with the latest trends so that the stakeholders and CXOs can derive benefits from the trends and generate good revenues.
Demography forms an important part of the growth pattern of all the markets. Diving deep into the demographics enables maximum output from specific areas. The TMR Research team assesses every region and picks out the vital points that have a large impact on the growth of a market.
The analysts at TMR Research conduct an all-round analysis on the competitive landscape of the market. The observations recorded by the analysts are added to the reports so that every stakeholder gets a glimpse of the competitive scenario and frame their business plans according to the situation.
The COVID-19 outbreak has changed the growth projections of numerous sectors and businesses. The analysts at TMR Research have conducted a conscientious survey on the markets after the pandemic struck. The analysts have put forth their brilliant and well-researched opinions in the report. The opinions will help the stakeholders to plan their strategy accordingly.
The reports offer answers to the top 7 questions that revolve around the growth of the market
Flat 10% discount on Single User License if you prebook this report
Flat 10% discount on Multiple User License if you prebook this report
Flat 10% discount on Corporate License if you prebook this report